SARS-CoV-2 Spike protein (S1, E484K, K417N, N501Y, His Tag)
| Z03531 | |
|
|
|
|
|
|
| Ask us a question | |
IVD Raw Materials
| Z03531 | |
|
|
|
|
|
|
| Ask us a question | |
| Species | SARS-CoV-2 | ||||
| Protein Construction |
Expressed with the mutations of E484K, K417N, N501Y.
|
||||
| Purity | > 90% as analyzed by SDS-PAGE | ||||
| Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | ||||
| Biological Activity | SARS-CoV-2 Spike protein (S1, E484K, K417N, N501Y, His Tag) can bind with human ACE2 (Cat. No.: Z03484) in functional ELISA assay. | ||||
| Expression System | 293 Cells | ||||
| Theoretical Molecular Weight | 79 kDa | ||||
| Formulation | Supplied as a solution in PBS pH 7.4 | ||||
| Concentration | Please refer to the COA for the specific lot. | ||||
| Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -20°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain. A variant known as 20H/501Y.V2, from the B.1.351 lineage of coronaviruses, was first identified in South Africa in December. The World Health Organization named it Beta. The Key mutations of this variant include E484K, K417N, N501Y, which may help the virus latch on more tightly to human cells evade some kinds of antibodies. |
| Synonyms | Lineage B.1.351; Beta variant; 20H/501Y.V2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.